Hint mode is switched on Switch off
For swift navigation between sections

Organization: Infant Bacterial Therapeutics
LEI 2138008KVBXCRJGP6Z26

Organization name
Infant Bacterial Therapeutics AB
Country name
Sweden
Country of registration
Sweden
Industry
Pharmaceutical Preparation and Biotechnology
Bond debt
-

explore the most comprehensive database

800 000

bonds globally

Over 400

pricing sources

80 000

stocks

9 000

ETF

track your portfolio in the most efficient way
Bond Search
Watchlist
Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Latest data on

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Infant Bacterial Therapeutics AB (IBT) is a clinical-stage pharmaceutical company. It develops drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. IBT is developing its drug candidate IBP-9414 to prevent NEC in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk.

Awards

Documentation

Stocks

Bond debt by currency

Show more Hide

Codes

  • LEI
    2138008KVBXCRJGP6Z26
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS

Credit and ESG Ratings

Macroeconomic Indicators - Infant Bacterial Therapeutics

Registration is required to get access.